Table 4.
Statistical comparison of key rosuvastatin, simvastatin, and simvastatin acid parameters following co-administration of rosuvastatin (20 mg) or simvastatin (40 mg) with fostamatinib (100 mg twice daily)
| Analyte | Parameter (units) | Treatment | n | Geometric LS mean | Statin + fostamatinib/statin alone | |
|---|---|---|---|---|---|---|
| Ratio (%) | 90 % CI | |||||
| Rosuvastatin | AUC (ng·h/mL) | Rosuvastatin alone | 21 | 93.7 | ||
| Rosuvastatin + fostamatinib | 21 | 183.4 | 195.6 | 177.6–215.3 | ||
| AUCt (ng·h/mL) | Rosuvastatin alone | 21 | 92.2 | |||
| Rosuvastatin + fostamatinib | 21 | 181.6 | 197.1 | 178.84–217.3 | ||
| C max (ng/mL) | Rosuvastatin alone | 21 | 10.6 | |||
| Rosuvastatin + fostamatinib | 21 | 19.9 | 188.4 | 169.4–209.6 | ||
| Simvastatin | AUC (ng·h/mL) | Simvastatin alone | 21 | 27.5 | ||
| Simvastatin + fostamatinib | 19 | 45.1 | 164.1 | 133.1–202.4 | ||
| AUCt (ng·h/mL) | Simvastatin alone | 21 | 26.1 | |||
| Simvastatin + fostamatinib | 19 | 44.4 | 170.1 | 137.1–211.0 | ||
| C max (ng/mL) | Simvastatin alone | 21 | 6.5 | |||
| Simvastatin + fostamatinib | 19 | 13.9 | 212.5 | 164.7–274.3 | ||
| Simvastatin acid | AUCt (ng·h/mL) | Simvastatin alone | 21 | 12.6 | ||
| Simvastatin + fostamatinib | 19 | 22.0 | 174.2 | 150.0–202.2 | ||
| C max (ng/mL) | Simvastatin alone | 21 | 1.4 | |||
| Simvastatin + fostamatinib | 19 | 2.6 | 182.8 | 156.7–213.3 | ||
Results based on linear model with fixed effects for treatment and subject
AUC area under the plasma concentration–time curve from zero to infinity, AUC t AUC from zero to the time of the last measurable concentration, CI confidence interval, C max, maximum plasma concentration, LS least-squares